bioMérieux Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
bioMérieux wird ein jährliches Gewinn- und Umsatzwachstum von 14.1% bzw. 7.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.4% betragen.
Wichtige Informationen
13.7%
Wachstumsrate der Gewinne
13.5%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 14.1% |
| Wachstumsrate der Einnahmen | 7.4% |
| Zukünftige Eigenkapitalrendite | 12.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 01 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08
bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17Recent updates
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?
Dec 03Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 4,540 | 608 | 467 | 880 | 12 |
| 12/31/2025 | 4,215 | 537 | 413 | 807 | 13 |
| 12/31/2024 | 3,940 | 464 | 355 | 726 | 13 |
| 6/30/2024 | 3,807 | 411 | 156 | 495 | N/A |
| 3/31/2024 | 3,741 | 384 | 132 | 470 | N/A |
| 12/31/2023 | 3,675 | 358 | 107 | 445 | N/A |
| 9/30/2023 | 3,688 | 372 | 140 | 459 | N/A |
| 6/30/2023 | 3,701 | 386 | 172 | 472 | N/A |
| 3/31/2023 | 3,645 | 419 | 180 | 474 | N/A |
| 12/31/2022 | 3,589 | 452 | 188 | 475 | N/A |
| 9/30/2022 | 3,525 | 502 | 297 | 583 | N/A |
| 6/30/2022 | 3,460 | 552 | 406 | 690 | N/A |
| 3/31/2022 | 3,418 | 577 | 470 | 757 | N/A |
| 12/31/2021 | 3,376 | 601 | 535 | 825 | N/A |
| 9/30/2021 | 3,296 | 555 | 424 | 716 | N/A |
| 6/30/2021 | 3,216 | 509 | 314 | 608 | N/A |
| 3/31/2021 | 3,167 | 457 | 310 | 595 | N/A |
| 12/31/2020 | 3,118 | 404 | 305 | 583 | N/A |
| 9/30/2020 | 2,997 | 355 | 261 | 538 | N/A |
| 6/30/2020 | 2,876 | 305 | 217 | 493 | N/A |
| 3/31/2020 | 2,775 | 289 | 176 | 451 | N/A |
| 12/31/2019 | 2,675 | 273 | 135 | 408 | N/A |
| 9/30/2019 | 2,601 | 268 | 160 | 419 | N/A |
| 6/30/2019 | 2,527 | 263 | 185 | 431 | N/A |
| 3/31/2019 | 2,474 | 260 | 179 | 415 | N/A |
| 12/31/2018 | 2,421 | 257 | 173 | 400 | N/A |
| 9/30/2018 | 2,372 | 264 | 162 | 370 | N/A |
| 6/30/2018 | 2,323 | 271 | 150 | 340 | N/A |
| 3/31/2018 | 2,306 | 255 | N/A | 341 | N/A |
| 12/31/2017 | 2,288 | 238 | N/A | 341 | N/A |
| 9/30/2017 | 2,262 | 216 | N/A | 340 | N/A |
| 6/30/2017 | 2,237 | 195 | N/A | 339 | N/A |
| 3/31/2017 | 2,170 | 187 | N/A | 337 | N/A |
| 12/31/2016 | 2,103 | 179 | N/A | 336 | N/A |
| 9/30/2016 | 2,068 | 158 | N/A | 339 | N/A |
| 6/30/2016 | 2,032 | 137 | N/A | 342 | N/A |
| 3/31/2016 | 1,998 | 124 | N/A | 326 | N/A |
| 12/31/2015 | 1,965 | 111 | N/A | 310 | N/A |
| 9/30/2015 | 1,908 | 127 | N/A | N/A | N/A |
| 6/30/2015 | 1,851 | 144 | N/A | 301 | N/A |
| 3/31/2015 | 1,775 | 140 | N/A | 300 | N/A |
| 12/31/2014 | 1,698 | 135 | N/A | 298 | N/A |
| 9/30/2014 | 1,656 | 135 | N/A | N/A | N/A |
| 6/30/2014 | 1,614 | 135 | N/A | 246 | N/A |
| 3/31/2014 | 1,601 | 150 | N/A | 243 | N/A |
| 12/31/2013 | 1,588 | 164 | N/A | 241 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BIMDas prognostizierte Gewinnwachstum (14.1% pro Jahr) liegt über der Sparquote (1.1%).
Ertrag vs. Markt: BIMDie Erträge des Unternehmens (14.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (11% pro Jahr).
Hohe Wachstumserträge: BIMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: BIMDie Einnahmen des Unternehmens (7.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.8% pro Jahr).
Hohe Wachstumseinnahmen: BIMDie Einnahmen des Unternehmens (7.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BIMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.4%).